|
|
|
Insider
Information: |
Landry Robert E |
Relationship: |
EVP Finance CFO |
City: |
Tarrytown |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
1 |
|
Direct
Shares |
23,693 |
|
Indirect Shares
|
270 |
|
|
Direct
Value |
$23,733,989 |
|
|
Indirect Value
|
$270,467 |
|
|
Total
Shares |
23,963 |
|
|
Total
Value |
$24,004,456 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
1
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
1.0
|
Percentage
Gain/Loss : |
0.0%
|
16.2%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Regeneron Pharmaceuticals Inc |
REGN |
EVP Finance CFO |
2024-02-02 |
23,693 |
2024-02-02 |
270 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
158 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 7
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2019-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,625 |
24,973 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-02-12 |
4 |
OE |
$272.70 |
$136,350 |
D/D |
500 |
25,473 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-02-12 |
4 |
D |
$402.34 |
$158,120 |
D/D |
(393) |
25,080 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-02-13 |
4 |
AS |
$398.63 |
$42,806 |
D/D |
(107) |
24,973 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-02-24 |
4 |
D |
$406.59 |
$319,580 |
D/D |
(786) |
25,187 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-02-24 |
4 |
OE |
$272.70 |
$272,700 |
D/D |
1,000 |
25,973 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-02-25 |
4 |
AS |
$438.00 |
$96,088 |
D/D |
(214) |
25,173 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-02-25 |
4 |
OE |
$272.70 |
$272,700 |
D/D |
1,000 |
26,187 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-02-25 |
4 |
D |
$447.30 |
$357,840 |
D/D |
(800) |
25,387 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-02-26 |
4 |
AS |
$452.04 |
$91,242 |
D/D |
(200) |
24,973 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-04-01 |
4 |
AS |
$478.97 |
$292,811 |
D/D |
(600) |
24,373 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-04-01 |
4 |
OE |
$272.70 |
$1,636,200 |
D/D |
6,000 |
26,888 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-04-01 |
4 |
D |
$488.20 |
$2,268,735 |
D/D |
(4,647) |
25,726 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-04-02 |
4 |
OE |
$272.70 |
$818,100 |
D/D |
3,000 |
28,726 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-04-02 |
4 |
D |
$492.05 |
$1,140,080 |
D/D |
(2,317) |
26,409 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-04-02 |
4 |
AS |
$495.24 |
$52,068 |
D/D |
(105) |
25,056 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-04-02 |
4 |
AS |
$483.51 |
$610,672 |
D/D |
(1,248) |
25,161 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-04-03 |
4 |
AS |
$489.50 |
$337,592 |
D/D |
(683) |
24,373 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-04-06 |
4 |
D |
$499.95 |
$1,151,885 |
D/D |
(2,304) |
25,069 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-04-06 |
4 |
OE |
$272.70 |
$818,100 |
D/D |
3,000 |
27,373 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-04-07 |
4 |
AS |
$497.50 |
$346,271 |
D/D |
(696) |
24,373 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-04-09 |
4 |
OE |
$272.70 |
$954,450 |
D/D |
3,500 |
27,873 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-04-09 |
4 |
D |
$508.25 |
$1,358,044 |
D/D |
(2,672) |
25,201 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-04-13 |
4 |
AS |
$505.60 |
$422,108 |
D/D |
(828) |
24,373 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
EVP Finance CFO |
|
2020-04-14 |
4 |
D |
$521.45 |
$1,380,278 |
D/D |
(2,647) |
25,226 |
0 |
- |
|
158 Records found
|
|
Page 1 of 7 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|